Continuous Manufacturing Project Deliverables


In response to growing interest in continuous manufacturing in the pharmaceutical industry, the Formulation Research Subcommittee launched the Continuous Manufacturing Project.

In Japan, with the aim of promoting the adoption of continuous manufacturing technology, research findings from several research groups under the Japan Agency for Medical Research and Development (AMED)—including the document “Points to Consider Regarding Continuous Manufacturing”—have already been published on the National Institute of Health Sciences (NIHS) website.Internationally, continuous manufacturing has been adopted as a quality topic by the ICH, and work on developing guidelines has begun. All currently available documents related to continuous manufacturing—including the ICH guidelines expected to be issued in the future—outline high-level requirements andand points for consideration. Consequently, many pharmaceutical companies are struggling to determine specific implementation strategies when actually introducing this technology and considering its application in commercial manufacturing, or—anticipating such challenges—have not yet proceeded with its adoption.

In this project, with the aim of helping to promote the adoption of this manufacturing technology in the pharmaceutical industry, we have created a document intended to provide specific examples of process development—examples not covered in the aforementioned guidelines and guidance documents—focusing on oral solid dosage forms, which are commonly selected.This document follows the development concept of the “Sakura Kaika Tablet P2 Mock” established by the Sakura Kaika Tablet Mock Subcommittee* —which has already been published—and presents an example of a process development methodology that applies the Quality by Design (QbD) approach to the continuous production of the same Sakura Kaika Tablet.It is designed to facilitate comparison with the “Sakura Kaika Tablet P2 Mock” by highlighting considerations for establishing control strategies based on differences in production methods. The content presented in this document is merely one example; while a rigid application of this case study may not always be effective or efficient, we hope it will serve as a useful reference when conducting analyses tailored to actual circumstances.

“An Example of the Approach to Developing Management Strategies for Continuous Production Based on CMA” Document (PDF file, 2.4 MB)

  • *
    Ministry of Health, Labour and Welfare Scientific Research Grant: Comprehensive Research Project on Regulatory Science for Pharmaceuticals and Medical Devices, Heisei 24–26: Research on Quality Assurance Throughout the Life Cycle of Pharmaceutical Preparations—Sakura Kaika Tablet Mock Subcommittee

Share this page

TOP